Abstract
The value of the rheumatoid arthritis (RA) market currently stands at
approximately US$11.6 billion and is continuing to grow, driven mainly by the
biologic DMARDs. It is dominated by five major pharma companies: Abbott,
Amgen, Johnson & Johnson, Schering-Plough and Wyeth, which between them market
three of the most successful biologics, the tumour necrosis factor inhibitors
Enbrel (etanercept), Remicade (infliximab) and Humira (adalimumab).
Research into new treatments is intense, driven by the need for safer and even
more effective medications with more convenient dosing schedules.
GlaxoSmithKline, Johnson & Johnson, Roche, Schering-Plough and UCB all have
biologics in the late phases of development, while Pfizer is pinning its hopes
on its oral kinase inhibitors, which are currently in Phase II development. As
these new therapies come on board and the market becomes more competitive, the
prospects for RA patients can only improve.
This report provides a complete assessment of the market' s potential
This new management report provides a complete examination of the RA market
and its prospects in the medium term. Packed with analysis and forecasts,
anyone needing to understand the drivers of this fast growing sector need look
no further.
Providing…
- Detailed assessment and 5-year forecasts for current leading products by
value
- A detailed review and assessment of up and coming products
- Unique product assessment and scoring
Major approaches
- Adenosine receptor antagonist
- B-cell targeted therapy
- Cathepsin-S inhibitors
- Chemokine receptor antagonists
- DHODH inhibitors
- Glucocorticoids
- Interleukin inhibitors
- Kinase inhibitors
- Lymphotoxin beta and light pathway inhibitor
- Non-steroidal anti-inflammatory drugs
- RANK ligand inhibitor
- T-cell co-stimulation modulator
- TNF inhibitors
- Traditional disease-modifying anti-rheumatic drugs
View Cart
